Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, Forchhammer S, Grimmel C, Mertens PR, Hailfinger S, Dunn SE, Garbe C, Schittek B.

Mol Cancer Res. 2018 May 9. doi: 10.1158/1541-7786.MCR-17-0528. [Epub ahead of print]

PMID:
29743296
2.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 May 1. pii: bio.032656. doi: 10.1242/bio.032656. [Epub ahead of print]

3.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

4.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

PMID:
29030332
5.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.

PMID:
28724666
6.

Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.

Niessner H, Kosnopfel C, Sinnberg T, Beck D, Krieg K, Wanke I, Lasithiotakis K, Bonin M, Garbe C, Meier F.

Exp Dermatol. 2017 Jul;26(7):598-606. doi: 10.1111/exd.13372.

PMID:
28423208
7.

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.

Kosnopfel C, Sinnberg T, Sauer B, Niessner H, Schmitt A, Makino E, Forschner A, Hailfinger S, Garbe C, Schittek B.

Oncotarget. 2017 May 30;8(22):35761-35775. doi: 10.18632/oncotarget.16204.

8.

Nutritional control of IL-23/Th17-mediated autoimmune disease through HO-1/STAT3 activation.

Brück J, Holstein J, Glocova I, Seidel U, Geisel J, Kanno T, Kumagai J, Mato N, Sudowe S, Widmaier K, Sinnberg T, Yazdi AS, Eberle FC, Hirahara K, Nakayama T, Röcken M, Ghoreschi K.

Sci Rep. 2017 Mar 14;7:44482. doi: 10.1038/srep44482.

9.
10.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. Review.

PMID:
28169047
11.

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3. Review.

PMID:
28162869
12.

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.

Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. Epub 2016 Jun 15. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1361.

13.

Casein kinase 1α has a non-redundant and dominant role within the CK1 family in melanoma progression.

Sinnberg T, Wang J, Sauer B, Schittek B.

BMC Cancer. 2016 Aug 3;16:594. doi: 10.1186/s12885-016-2643-0.

14.

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.

Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.

EBioMedicine. 2016 Jun;8:132-149. doi: 10.1016/j.ebiom.2016.04.037. Epub 2016 May 1.

15.

UVA-Irradiation Induces Melanoma Invasion via the Enhanced Warburg Effect.

Kamenisch Y, Baban TS, Schuller W, von Thaler AK, Sinnberg T, Metzler G, Bauer J, Schittek B, Garbe C, Rocken M, Berneburg M.

J Invest Dermatol. 2016 Sep;136(9):1866-75. doi: 10.1016/j.jid.2016.02.815. Epub 2016 May 13. Review.

16.

Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.

Dhayade S, Kaesler S, Sinnberg T, Dobrowinski H, Peters S, Naumann U, Liu H, Hunger RE, Thunemann M, Biedermann T, Schittek B, Simon HU, Feil S, Feil R.

Cell Rep. 2016 Mar 22;14(11):2599-610. doi: 10.1016/j.celrep.2016.02.028. Epub 2016 Mar 10.

17.

PTEN regulates IGF-1R-mediated therapy resistance in melanoma.

Wang J, Sinnberg T, Niessner H, Dölker R, Sauer B, Kempf WE, Meier F, Leslie N, Schittek B.

Pigment Cell Melanoma Res. 2015 Sep;28(5):572-89. doi: 10.1111/pcmr.12390.

PMID:
26112748
18.

Molecular mechanisms of pharmacological doses of ascorbate on cancer cells.

Venturelli S, Sinnberg TW, Niessner H, Busch C.

Wien Med Wochenschr. 2015 Jun;165(11-12):251-7. doi: 10.1007/s10354-015-0356-7. Epub 2015 Jun 12. Review.

PMID:
26065536
19.

Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis.

Schittek B, Sinnberg T.

Mol Cancer. 2014 Oct 11;13:231. doi: 10.1186/1476-4598-13-231. Review.

20.

Epigenetic impacts of ascorbate on human metastatic melanoma cells.

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C.

Front Oncol. 2014 Aug 25;4:227. doi: 10.3389/fonc.2014.00227. eCollection 2014.

21.

Sulforaphane protects from T cell-mediated autoimmune disease by inhibition of IL-23 and IL-12 in dendritic cells.

Geisel J, Brück J, Glocova I, Dengler K, Sinnberg T, Rothfuss O, Walter M, Schulze-Osthoff K, Röcken M, Ghoreschi K.

J Immunol. 2014 Apr 15;192(8):3530-9. doi: 10.4049/jimmunol.1300556. Epub 2014 Mar 17.

22.

Y-box binding protein 1--a prognostic marker and target in tumour therapy.

Kosnopfel C, Sinnberg T, Schittek B.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):61-70. doi: 10.1016/j.ejcb.2013.11.007. Epub 2013 Dec 27. Review.

PMID:
24461929
23.

The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines.

Sinnberg T, Noor S, Venturelli S, Berger A, Schuler P, Garbe C, Busch C.

J Cell Mol Med. 2014 Mar;18(3):530-41. doi: 10.1111/jcmm.12207. Epub 2013 Dec 14.

24.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.

25.

Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.

Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F.

Sci Signal. 2013 Jan 29;6(260):ra7. doi: 10.1126/scisignal.2003057.

26.

miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes.

Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, Diederichs S, Eichmüller SB.

J Invest Dermatol. 2013 Mar;133(3):768-775. doi: 10.1038/jid.2012.357. Epub 2012 Nov 15.

27.

MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.

Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserhoff A, Schittek B.

Exp Dermatol. 2012 Apr;21(4):265-70. doi: 10.1111/j.1600-0625.2012.01448.x.

PMID:
22417301
28.

Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.

Schott S, Niessner H, Sinnberg T, Venturelli S, Berger A, Ikenberg K, Villanueva J, Meier F, Garbe C, Busch C.

Int J Cancer. 2012 Nov 1;131(9):2165-74. doi: 10.1002/ijc.27476. Epub 2012 Mar 15.

29.

Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo.

Krochmann J, Sinnberg T, Meier F, Garbe C, Busch C.

Pigment Cell Melanoma Res. 2012 Jan;25(1):113-4. doi: 10.1111/j.1755-148X.2011.00914.x. Epub 2011 Oct 13. No abstract available.

PMID:
21974864
30.

β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance.

Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C, Schittek B.

PLoS One. 2011;6(8):e23429. doi: 10.1371/journal.pone.0023429. Epub 2011 Aug 17.

31.

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.

32.

Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis.

Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, Nahnsen S, Schwarz M, Garbe C, Schittek B.

Cancer Res. 2010 Sep 1;70(17):6999-7009. doi: 10.1158/0008-5472.CAN-10-0645. Epub 2010 Aug 10.

33.

Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus.

Senyürek I, Paulmann M, Sinnberg T, Kalbacher H, Deeg M, Gutsmann T, Hermes M, Kohler T, Götz F, Wolz C, Peschel A, Schittek B.

Antimicrob Agents Chemother. 2009 Jun;53(6):2499-509. doi: 10.1128/AAC.01679-08. Epub 2009 Apr 13.

34.

Isolation of three stem cell lines from human sacrococcygeal teratomas.

Busch C, Bareiss PM, Sinnberg T, Just L, Wehrmann M, Fuchs J, Garbe C, Drews U.

J Pathol. 2009 Mar;217(4):589-96. doi: 10.1002/path.2486.

PMID:
19142973
35.

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F.

J Invest Dermatol. 2009 Jun;129(6):1500-15. doi: 10.1038/jid.2008.379. Epub 2008 Dec 11.

36.

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.

Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE.

J Invest Dermatol. 2008 Aug;128(8):2013-23. doi: 10.1038/jid.2008.44. Epub 2008 Mar 6.

Supplemental Content

Loading ...
Support Center